Mirum Pharmaceuticals (MIRM) Short term Debt (2020 - 2023)

Mirum Pharmaceuticals' Short term Debt history runs 4 years deep, the most recent figure standing at $1.1 million for Q1 2023.

• In Q1 2023, Short term Debt fell 45.39% year-over-year to $1.1 million; the TTM figure through Mar 2023 stood at $1.1 million (down 45.39% YoY), while the FY2022 annual figure was $1.1 million, down 45.39% from the prior year.
• Short term Debt was $1.1 million for Q1 2023 at Mirum Pharmaceuticals, roughly flat from $1.1 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $2.2 million in Q2 2021 to a low of $847000.0 in Q3 2021.
• Historically, Short term Debt has averaged $1.5 million across 4 years, with a median of $1.5 million in 2020.
• Biggest YoY gain for Short term Debt was 114.62% in 2022; the steepest drop was 45.39% in 2022.
• A 4-year view of Short term Debt shows it stood at $1.3 million in 2020, then surged by 57.91% to $2.0 million in 2021, then plunged by 45.39% to $1.1 million in 2022, then changed by 0.0% to $1.1 million in 2023.
• The last three Short term Debt figures came in at $1.1 million (Q1 2023), $1.1 million (Q4 2022), and $1.8 million (Q3 2022), per Business Quant data.